Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS AUGUST ISSUE PUBLISHED
  • AUGUST 2020 Issue has been successfully launched on 1 August 2020.

Abstract

REVIEW ON CHEMISTRY AND PHARMACOLOGY OF DABIGATRAN A POTENT ANTICOAGULANT

Jyoti Thakur, Amit Chaudhary, Diksha Choudhary, Bhupendra Tomar, M. P. Tanwar, G. C. Verma.

ABSTRACT

Direct Coagulase Inhibitors category of medication that acts as anticoagulants (delaying blood clotting) by directly inhibiting the accelerator coagulase (factor II a). Thrombin is a serine protease that plays a key role in blood clotting, which makes it a promising target for the treatment of thrombotic diseases. Anticoagulant a drug called as blood diluter prevents, treats, and reduces the risk of blood clots. They work by preventing blood coagulation to form a clot in the vital organs such as the heart, lungs, and brain. It is a direct thrombin inhibitor, and functions by directly inhibiting both free and fibrin- bound thrombin. There is one specific antidote, idarucizumab, which reverses the effect of dabigatran. It is a competitive, synthetic, and reversible direct thrombin inhibitor. By inhibiting thrombin it disrupts the coagulation cascade and inhibits the formation of clots. It is used to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. It also decreases the risk of venous thromboembolic events in patients that have undergone total hip or knee replacement surgery. We designed and synthesized dabigatran etexilate acid salt. The biological evaluations reveal that the compounds possess moderate activity of antiplatelet aggregation induced by thrombin in vitro.

Keywords: Dabigatran Etexilate; Thrombin inhibitor; Anti coagulant; Atrial fibrillation.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More